Pharmaceuticals 19 March 2026

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics, Incorporated shares surged Monday, after the company reported its experimental oral hair-loss treatment, VDPHL01, hit all main and key secondary endpoints in a Phase 2/3 study of men with mild-to-moderate pattern hair loss. The Phase 2/3 trial—a mid- to late-stage human study—is designed to assess safety and efficacy ahead of a potential approval filing.

27 April 2026

NYSE:MANE·Pharmaceuticals·Stock Market

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Pharmaceuticals caught Wall Street’s attention again—investors now have more to chew on after a U.S. drug-pricing agreement, a unique FDA approval, and new backing from analysts, all ahead of next week’s earnings report.

24 April 2026

NASDAQ:REGN·Pharmaceuticals·Stock Market

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment.

21 April 2026

NASDAQ:AMZN·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones.

21 April 2026

Biotechnology·NYSE:LLY·Pharmaceuticals

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer picked up a new short-term catalyst Monday, with the U.S. Food and Drug Administration handing a priority review to its Padcev submission for bladder cancer. The stock gained roughly 0.8%, trading at $27.78 in the afternoon, drawing renewed attention as the company pushes ahead with a wider pipeline.

20 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson topped Wall Street’s Q1 expectations on Tuesday, helped by surging sales from the cancer therapy Darzalex and the psoriasis drug Tremfya. Those gains made up for a sharp decline in Stelara, which used to be a major driver. Revenue climbed 9.9% to $24.1 billion, beating forecasts of $23.6 billion. Adjusted earnings reached $2.70 a share, also above the $2.66 consensus. The company lifted its 2026 outlook.

14 April 2026

Earnings·NYSE:JNJ·Pharmaceuticals·Stock Market

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics yanked its European application for VIOKAT on Tuesday, just a day after striking a $2.9 billion cash deal to be acquired by Neurocrine Biosciences. That move halts a regulatory review Soleno had earlier projected might wrap up by mid-2026.

7 April 2026

Biotechnology·NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences is set to buy Soleno Therapeutics Inc. in a $2.9 billion all-cash transaction announced Monday, offering $53 per share to Soleno holders. Shares of the rare-disease specialist traded at $52.25, just shy of the bid.

7 April 2026

NASDAQ:NBIX·NASDAQ:SLNO·Pharmaceuticals·Stock Market

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Between April 3 and April 6, a trio of reports drawing on fourth-quarter 13F filings detailed that Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners each cut back on Pfizer positions—together unloading 740,174 shares. On Monday, Pfizer stock slipped roughly 0.7% to $28.12 in U.S. trading.

6 April 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Shares of Apellis Pharmaceuticals hovered close to Biogen’s $41-per-share bid on Wednesday, following news of the $5.6 billion cash-and-contingent deal announced a day earlier. The stock last traded at $40.23 in the U.S. session.

1 April 2026

NASDAQ:APLS·NASDAQ:BIIB·Pharmaceuticals·Stock Market

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer hit a new 52-week high Tuesday, lifted by upbeat analyst notes and a string of pipeline news fueling demand. Shares last changed hands at $27.87 late in the morning, having reached $28.30 earlier—eclipsing the earlier high-water mark of $27.92.

31 March 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly kicks off the week with a fresh pipeline pact in hand. Insilico Medicine on Sunday announced it struck a global licensing and research deal with the U.S. pharma giant, a tie-up valued at as much as $2.75 billion. Lilly shares finished Friday at $878.24, off 2.1%. The stock sits more than 22% beneath its Jan. 8 peak.

29 March 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals ended Friday down 4.6% at $433.07, reacting to fresh U.S. safety label updates for its flagship cystic fibrosis therapies. Despite the pressure from the label news, BMO Capital’s Evan David Seigerman stood by his outperform call and kept the price target at $600.

28 March 2026

NASDAQ:VRTX·Pharmaceuticals·Stock Market

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

In U.S. premarket action Thursday, Terns Pharmaceuticals was pegged at $52.86, matching Wednesday’s close and sitting roughly 14 cents under Merck’s $6.7 billion all-cash bid for the biotech. Terns had surged 5.8% by the end of Wednesday’s session.

26 March 2026

NASDAQ:TERN·NYSE:MRK·Pharmaceuticals·Stock Market

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion cash deal, offering $53 per share, the companies said Wednesday. The move hands Merck an experimental leukemia drug and underlines its push into oncology. The announcement followed a Financial Times report earlier in the day that discussions were already advanced.

25 March 2026

NASDAQ:TERN·NYSE:MRK·Pharmaceuticals

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk slipped 1.5% to 237.90 Danish crowns in Copenhagen on Thursday, despite the FDA signing off on a higher-dose Wegovy injection. The stock remained in the red after Eli Lilly unveiled new obesity drug results, and as Reuters flagged that semaglutide patent expiry in India could clear the way for lower-cost generics of the compound found in both Wegovy and Ozempic.

20 March 2026

CSE:NOVO.B·Pharmaceuticals·Stock Market

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.

19 March 2026

Health News·NYSE:LLY·Pharmaceuticals·Stock Market

Pharmaceuticals 19 March 2026 - 27 April 2026